Shanghai Henlius Biotech, Inc. (HKG: 2696) announced marketing approval from Health Canada for Bildyos (denosumab 60 mg/mL) and Tuzemty (denosumab 120 mg/mL) – biosimilar versions of Amgen’s RANKL inhibitors Prolia® and Xgeva® – expanding the Organon partnership to Canada and advancing Henlius’s global biosimilar commercialization strategy.
Regulatory Milestone
Item
Detail
Agency
Health Canada
Products
Bildyos (60 mg/mL) + Tuzemty (120 mg/mL)
Company
Shanghai Henlius Biotech, Inc. (HKG: 2696)
Reference Products
Prolia® + Xgeva® (denosumab, Amgen)
Mechanism
RANKL inhibition – anti‑resorptive bone therapy
Commercial Partner
Organon (NYSE: OGN) – exclusive rights outside China
Partnership Date
2022 licensing deal
Canada Launch
Expected 2026
Approved Indications
Bildyos (60 mg/mL) – Prolia® Biosimilar
Indication
Patient Population
Postmenopausal osteoporosis
High fracture risk
Male osteoporosis
High fracture risk
Glucocorticoid‑induced osteoporosis
Men and women, high fracture risk
Androgen deprivation therapy
Men with nonmetastatic prostate cancer – bone mass increase
Aromatase inhibitor therapy
Women with breast cancer – bone mass increase
Tuzemty (120 mg/mL) – Xgeva® Biosimilar
Indication
Patient Population
Skeletal‑related events (SRE) prevention
Multiple myeloma + solid tumor bone metastases
Giant cell tumor of bone
Unresectable or surgery‑associated severe morbidity
Hypercalcemia of malignancy
Refractory to bisphosphonate therapy
Partnership Structure – Henlius + Organon
Dimension
Henlius Responsibilities
Organon Responsibilities
Development/Manufacturing
R&D, biologics production, quality control
–
Commercialization
–
Exclusive rights outside China (US, Canada, EU, etc.)
Henlius/Organon first‑mover in Canada; manufacturing quality differentiation
Market Impact & Outlook
Biosimilar Market Dynamics: Denosumab patent expiry 2025‑2026 (US/EU/Canada) opens US$4+ billion biosimilar opportunity; RANKL inhibition mechanism established for osteoporosis and oncology bone health; biosimilar adoption driven by payer pressure (30‑50% discount vs. originator).
Henlius Global Expansion: Health Canada approval validates international regulatory capabilities; Organon partnership de‑risks commercial execution in unfamiliar markets; denosumab franchise adds to Henlius’s established trastuzumab, bevacizumab, adalimumab biosimilars – broad oncology/immunology portfolio.
Organon Commercial Leverage: Organon’s women’s health and bone health franchise (legacy Merck/MSD) provides physician access for Bildyos; oncology infrastructure supports Tuzemty hospital/specialty pharmacy distribution; Canada launch 2026 establishes precedent for US commercialization.
Manufacturing & Supply: Henlius’s Shanghai biologics facility supports multi‑product global supply; Organon inventory commitments provide revenue visibility; Health Canada GMP inspection clearance enables other Commonwealth market submissions (Australia, UK, New Zealand).
Revenue Trajectory: Estimated US$50‑80 million annual Canada sales peak (2028‑2030) assuming 25‑30% market share; US market entry 2027‑2028 adds US$300‑500 million potential; EU EMA submission 2026‑2027 for additional US$200‑300 million European opportunity.
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch timelines, market share projections, and partnership performance for Bildyos and Tuzemty. Actual results may differ due to competitive biosimilar entrants, payer reimbursement negotiations, and manufacturing supply chain constraints.-Fineline Info & Tech
By Fineline Cube